CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cellectis S.A.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$0.93−0.11 (-11.01%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
100.0%+3.8 pts over 5 years
Operating margin
-45.3%+37.5 pts over 5 years
Net margin
-92.7%+66.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +75.8% | +56.1% | +7.4% | +2.7% | |
| Gross profit | +75.8% | +61.2% | +8.2% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -24.1% | -27.1% | -65.3% | |
| Return on assets | -19.1% | -17.3% | -19.1% | |
| Current ratio | 5.56 | 6.06 | – | |
| Interest coverage | -9.5× | -2.6× | -0.6× | |
| Inventory turnover | – | 0.9× | – | |
| Capex to revenue | 30.6% | 86.3% | 3.2% | |
| Diluted shares | 35M | 43M | 100M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cellectis generated $279.14M from operations and spent $26.99M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$279.14M
Used
$26.99M
Capital expenditure$26.99M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-92.7%
×Asset turnover0.21×
×Equity multiplier3.42×
=Return on equity, FY2025-65.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -92.7% | 0.21× | 3.42× | -65.3% |
| FY2024 | -88.6% | 0.12× | 3.33× | -34.1% |
| FY2023 | -13385.3% | 0.00× | 2.94× | -99.7% |
| FY2022 | -553.6% | 0.06× | 1.90× | -62.6% |
| FY2021 | -376.3% | 0.07× | 1.69× | -45.2% |
| FY2020 | -158.8% | 0.11× | 1.56× | -27.1% |
| FY2019 | -672.1% | 0.03× | 1.34× | -28.2% |
| FY2018 | -618.1% | 0.03× | 1.24× | -23.3% |
| FY2017 | -394.5% | 0.08× | 1.24× | -37.0% |
| FY2016 | -150.1% | 0.13× | 1.26× | -24.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$67.59M
- Cash generatingOperating cash flow above zero-$39.40M
- Return on assets improvedROA up on the prior year-11.0% → -17.6%
- Earnings backed by cashOperating cash flow above net income-$39.40M vs -$67.59M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose– → –
- No dilutionShare count did not rise91M → 100M
- Gross margin improvedGross margin up on the prior year100.00% → 100.00%
- More efficientAsset turnover rose0.12 → 0.19